MMRC Clinical Trials

The MMRC has opened more than 40 Phase I and Phase II clinical trials of both novel compounds and combination approaches that are thought to be active against high-priority targets.

Select a trial below to view more information or use our specialized search engine to narrow your focus. For more information about MMRC-facilitated clinical trials, contact us or call 1-866-03-MMCT (6628).

Randomized Phase II Velcade® (bortezomib) and Dexamethasone, With and Without Elotuzumab
This phase II study will evaluate if the addition of elotuzumab to these two commonly used agents has any advantage over the use of Velcade® and dexamethasone alone in patients with relapsed or refractory multiple myeloma. Elotuzumab is a humanized anti-CS1... Read more
Phase I/II Study of MLN9708, Revlimid® (lenalidomide), and Dexamethasone
MLN9708 is an experimental oral second-generation proteasome inhibitor also being evaluated alone and in combination with several other agents in relapsed and/or refractory myeloma. It is in the same class of drugs as Velcade® (bortezomib). The main... Read more
Phase I/II AT7519 Alone or With Velcade® (bortezomib)
AT7519 is an experimental anti-cancer agent that prevents the growth and spread of myeloma cells by interfering with cell division; it is given intravenously. In laboratory and animal studies, AT7519 has been found to slow multiple myeloma, and has been found... Read more
Phase I Panobinostat and Carfilzomib
Laboratory and clinical studies suggest that enhanced activity against multiple myeloma may be obtained by combining agents from the two drug classes represented by panobinostat and carfilzomib. Panobinostat is a new kind of oral anti-cancer drug that blocks... Read more
Phase I Ganetespib (STA-9090) With and Without Velcade® (bortezomib)
The purpose of this study is to find out what effects, good and/or bad, that ganetespib alone and the combination of ganetespib and Velcade® (bortezomib) have on patients with relapsed or refractory multiple myeloma. The study will also assess the effect... Read more
Phase I Siltuximab in Asymptomatic Multiple Myeloma
Siltuximab (also known as CNTO 328) is monoclonal antibody that targets interleukin-6, which affects the immune system. It is given intravenously. The purpose of this study is to determine if siltuximab has an effect on the heart function in patients with... Read more